The estimated Net Worth of Jeffrey Francis Biunno is at least $395 Thousand dollars as of 18 December 2020. Mr Biunno owns over 7,490 units of CohBar Inc stock worth over $7,521 and over the last 7 years he sold CWBR stock worth over $0. In addition, he makes $387,500 as CFO and Treasurer & Sec. at CohBar Inc.
Mr has made over 10 trades of the CohBar Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 7,490 units of CWBR stock worth $3,221 on 18 December 2020.
The largest trade he's ever made was exercising 10,000 units of CohBar Inc stock on 21 February 2020 worth over $2,600. On average, Mr trades about 3,382 units every 24 days since 2018. As of 18 December 2020 he still owns at least 17,490 units of CohBar Inc stock.
You can see the complete history of Mr Biunno stock trades at the bottom of the page.
Jeffrey F. Biunno CPA, M.B.A., CPA, MBA is the CFO, Treasurer & Sec. at CohBar Inc.
As the CFO and Treasurer & Sec. of CohBar Inc, the total compensation of Mr MBA at CohBar Inc is $387,500. There are 3 executives at CohBar Inc getting paid more, with Steven Engle having the highest compensation of $2,410,850.
Mr MBA is 55, he's been the CFO and Treasurer & Sec. of CohBar Inc since . There are 10 older and 3 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.
Jeffrey's mailing address filed with the SEC is C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK, CA, 94025.
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy, and Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
CohBar Inc executives and other stock owners filed with the SEC include: